Hcr Formulations Profile
Key Indicators
- Authorised Capital ₹ 0.50 M
as on 11-01-2025
- Paid Up Capital ₹ 0.20 M
as on 11-01-2025
- Company Age 22 Year, 1 Month
- Last Filing with ROC 31 Mar 2024
- Revenue 7.04%
(FY 2022)
- Profit -36.28%
(FY 2022)
- Ebitda 34.93%
(FY 2022)
- Net Worth 7.43%
(FY 2022)
- Total Assets 21.01%
(FY 2022)
About Hcr Formulations
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 0.50 M and a paid-up capital of Rs 0.20 M, as per Ministry of Corporate Affairs (MCA) records.
Divyang Shah, Jagrutiben Shah, and Kushan Shah serve as directors at the Company.
- CIN/LLPIN
U24231GJ2002PTC041588
- Company No.
041588
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
27 Nov 2002
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Ahmedabad
Industry
Company Details
- Location
Ahmedabad, Gujarat, India
- Telephone
- Email Address
- Website
- Social Media
What products or services does Hcr Formulations Private Limited offer?
Hcr Formulations Private Limited offers a wide range of products and services, including Nutraceuticals & Dietary Supplements, Vitamin Tablets & Capsules, Healthcare Products & Aids, Health Drinks, Ayurvedic Pain Relief Oil, Muscle Pain Oil, Liver Supplement, Ayurvedic Liver Tablets Capsules.
Who are the key members and board of directors at Hcr Formulations?
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Kushan Shah  | Director | 30-Mar-2015 | Current |
| Divyang Shah | Director | 27-Nov-2002 | Current |
| Jagrutiben Shah | Director | 27-Nov-2002 | Current |
Financial Performance of Hcr Formulations.
Hcr Formulations Private Limited, for the financial year ended 2022, experienced modest growth in revenue, with a 7.04% increase. The company also saw a substantial fall in profitability, with a 36.28% decrease in profit. The company's net worth moved up by a moderate rise of 7.43%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Hcr Formulations?
In 2019, Hcr Formulations had a promoter holding of 52.31% and a public holding of 47.69%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Hcr Formulations?
Unlock and access historical data on people associated with Hcr Formulations, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Hcr Formulations, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Hcr Formulations's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
